Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Briumvi (ublituximab-xiiy)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ildong, LFB SA, Neuraxpharm, TG Therap

Drug class:

CD20 inhibitor

Related drugs:

SIBP-02 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

rituximab (176)

obinutuzumab (68)

epcoritamab-bysp (11)

rituximab-pvvr (6)

rituximab-abbs (6)

rituximab/hyaluronidase (5)

Rixathon (rituximab biosimilar) (4)

ibritumomab tiuxetan (3)

mosunetuzumab-axgb (2)

rituximab-arrx (2)

glofitamab-gxbm (1)

TQB2303 (rituximab biosimilar) (1)

odronextamab (1)

Ritucad (rituximab biosimilar) (1)

AcellBia (rituximab biosimilar) (0)

zuberitamab (0)

Avetux (rituximab biosimilar) (0)

BI 695500 (rituximab biosimilar) (0)

CIMAbior (rituximab biosimilar) (0)

DI Leu16 IL-2 (0)

GB241 (rituximab biosimilar) (0)

Halpryza (rituximab biosimilar) (0)

Hanlikon (rituximab biosimilar) (0)

Reditux (rituximab biosimilar) (0)

JHL1101 (rituximab biosimilar) (0)

Kikuzubam (rituximab biosimilar) (0)

MK-8808 (rituximab biosimilar) (0)

MabionCD20 (rituximab biosimilar) (0)

Mabtas (rituximab biosimilar) (0)

Novex (rituximab biosimilar) (0)

ocrelizumab (0)

Retuxira (rituximab biosimilar) (0)

SAIT101 (rituximab biosimilar) (0)

SIBP-02 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

›

No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	umbralisib + ublituximab-xiiy Sensitive: B - Late Trials umbralisib + ublituximab-xiiy Sensitive : B	umbralisib + ublituximab-xiiy Sensitive: B - Late Trials umbralisib + ublituximab-xiiy Sensitive : B
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B
IL2 elevation	Mantle Cell Lymphoma	IL2 elevation	Mantle Cell Lymphoma	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D
IL6 elevation	Mantle Cell Lymphoma	IL6 elevation	Mantle Cell Lymphoma	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D
TNFA elevation	Mantle Cell Lymphoma	TNFA elevation	Mantle Cell Lymphoma	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D